The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Fatigue, Hb, & inflammatory markers in patients with wAIHA treated with rilzabrutinib in LUMINA2
In this video, David Kuter, MD, Massachusetts General Hospital, Boston, MA, discusses an analysis of data from the LUMINA2 study (NCT05002777), which investigated the use of rilzabrutinib, a BTK inhibitor, for the treatment of warm autoimmune hemolytic anemia (wAIHA). Prof. Kuter highlights that a significant hemoglobin (Hb) response was observed in over half of patients treated, with increases in Hb and declines in inflammatory markers correlating with subsequent improvements in fatigue scores. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
